Facebook, Inc. (FB) Message Board

would be irresponsible if they gave out numbers.

Amarin believes Vascepa well positioned in triglyceride lowering market
The fly On The Wall
Amarin is well positioned to compete in the triglyceride lowering market. This is a large market which, based on market research, Amarin believes is currently underpenetrated due to limitations of existing therapies. Amarin's market research further suggests that clinicians value the data supporting Vascepa in the MARINE indication: in patients with very high (=500 mg/dL) triglyceride levels, Vascepa has been shown to lower triglycerides without increasing bad cholesterol (low-density lipoprotein cholesterol, or LDL-C) and with a tolerability and safety profile similar to placebo. Amarin formally launched Vascepa in the United States on January 28.

holding this one.

Upcoming Catalysts For These BioPharmas Provide Potential Upside
Updated February 28, 2013 By: Scott Matusow
Sarepta (SRPT)

There are many Sarepta bears who believe the drug will not receive early approval, and in my opinion, they are not considering the ever changing political landscape surrounding the FDA. Lawmakers have been putting additional pressure on the FDA to get drugs to market which are designed to treat rare diseases. DMD is a very rare disease that affects children - providing additional pressure for the FDA to grant accelerated approval here.

I wonder if the bears have read Section 902 of The FDA Safety and Innovation Act - "Breakthrough Therapies."

According to author Michael Mccaughan;

The provision creates a new section of the FD&C Act, and inserts it directly before the "Fast Track" and Accelerated Approval sections also included in FDASIA. That symbolic position indicates the intent: something that happens even earlier in drug development than the existing FDA mechanisms.

Also, it will be hard for the FDA to ignore Jenn McNary, mother of a child who suffers from DMD, who has been one of many strong advocates petitioning the organization to allow accelerated approval of Eteplirsen.
The chart has just begun making a couple of reversal candles indicating a higher move is possible once it breaks out of its current wedge. After this point, the stock could retest its former high of $45.

The Street 3/1 Fridays Mailbag

cheers

thanks all

happens all the time

got in cheap

anyone know?